NO20082874L - Antistoffer mot anyloid beta 4 med glykosylert i det variable omradet - Google Patents

Antistoffer mot anyloid beta 4 med glykosylert i det variable omradet

Info

Publication number
NO20082874L
NO20082874L NO20082874A NO20082874A NO20082874L NO 20082874 L NO20082874 L NO 20082874L NO 20082874 A NO20082874 A NO 20082874A NO 20082874 A NO20082874 A NO 20082874A NO 20082874 L NO20082874 L NO 20082874L
Authority
NO
Norway
Prior art keywords
glycosylated
antibodies
antibody
variable region
asn
Prior art date
Application number
NO20082874A
Other languages
English (en)
Other versions
NO346105B1 (no
Inventor
Manfred Brockhaus
Walter Huber
Hansruedi Loetscher
Karl Weyer
Hans Koll
Kurt Lang
Andreas Schaubmar
Diana Schuhbauer
Bernd Bohrmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082874L publication Critical patent/NO20082874L/no
Publication of NO346105B1 publication Critical patent/NO346105B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelsen er relatert til et renset antistoffmolekylpreparat som er karakterisert ved at minst ett antigenbindende sete omfatter en glykosylert asparagin (Asn) i den variable regionen av den tunge kjeden (VH)- Mer spesifikt er en farmasøytisk og en diagnostisk sammensetning omfattende nevnte antistoffmolekyl og antistoffblandinger tilveiebrakt som er i stand til å spesifikt gjenkjenne P-A4-peptidet/AP4. Den foreliggende oppfinnelsen er spesielt relatert til en blanding av antistoffer omfattende ett eller to glykosylerte antigenbindende seter med en glykosylert asparagin (Asn) i den variable regionen av den tunge kjeden, det vil si blandinger av isoformer av antistoffer som omfatter en glykosylert Asn i den variable regionen av den tunge kjeden (VI-,). Også angitt er sammensetninger eller antistoffpreparater omfattende de spesifikt glykosylerte antistoffisoformene. Videre er de farmasøytiske og diagnostiske anvendelsene for disse antistoffene tilveiebrakt. Antistoffisoformene kan for eksempel bli benyttet i den farmasøytiske intervensjonen av amyloidogenese eller amyloid plakkdannelse og/eller i diagnostikken av det samme.
NO20082874A 2005-12-12 2006-12-11 Antistoffer mot amyloid-beta-4 med glykosylert asparagin i den variable regionen NO346105B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05027090 2005-12-12
PCT/EP2006/011914 WO2007068429A1 (en) 2005-12-12 2006-12-11 Antibodies against amyloid beta 4 with glycosylated in the variable region

Publications (2)

Publication Number Publication Date
NO20082874L true NO20082874L (no) 2008-08-28
NO346105B1 NO346105B1 (no) 2022-02-21

Family

ID=37745986

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082874A NO346105B1 (no) 2005-12-12 2006-12-11 Antistoffer mot amyloid-beta-4 med glykosylert asparagin i den variable regionen

Country Status (34)

Country Link
US (2) US8906370B2 (no)
EP (2) EP1960428B1 (no)
JP (1) JP5145241B2 (no)
KR (2) KR20080077132A (no)
CN (2) CN102659943B (no)
AR (1) AR057233A1 (no)
AT (1) ATE517923T1 (no)
AU (1) AU2006326301B2 (no)
BR (1) BRPI0619605B8 (no)
CA (1) CA2632828C (no)
CR (1) CR10000A (no)
CY (1) CY1114783T1 (no)
DK (1) DK1960428T3 (no)
DO (1) DOP2006000278A (no)
EC (1) ECSP088524A (no)
ES (1) ES2368591T3 (no)
HK (2) HK1130066A1 (no)
IL (1) IL191004A (no)
JO (1) JO2824B1 (no)
MA (1) MA30038B1 (no)
MY (1) MY155286A (no)
NO (1) NO346105B1 (no)
NZ (1) NZ568241A (no)
PE (3) PE20100748A1 (no)
PL (1) PL1960428T3 (no)
PT (1) PT1960428E (no)
RS (1) RS52004B (no)
RU (1) RU2438706C2 (no)
SI (1) SI1960428T1 (no)
TW (1) TWI382990B (no)
UA (1) UA99097C2 (no)
UY (1) UY30003A1 (no)
WO (1) WO2007068429A1 (no)
ZA (1) ZA200805038B (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PE20100748A1 (es) * 2005-12-12 2010-11-12 Hoffmann La Roche Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh
US20110070225A1 (en) * 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
HUE037060T2 (hu) * 2007-06-29 2018-08-28 Hoffmann La Roche Javított immunglobulin-termeléshez vezetõ nehézlánc-mutáns
BRPI0815576A2 (pt) * 2007-08-20 2015-02-18 Glaxo Group Ltd Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo.
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
AU2009242453B2 (en) * 2008-05-02 2014-12-04 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20140213465A1 (en) * 2011-12-02 2014-07-31 Plaxgen, Inc. Plaque array methods and compositions for forming and detecting plaques
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
US20130116413A1 (en) * 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2013063284A1 (en) * 2011-10-25 2013-05-02 Onclave Therapeutics Antibody formulations and methods
CA2860543C (en) * 2012-03-08 2018-04-24 F. Hoffmann-La Roche Ag Abeta antibody formulation
AU2013307406B2 (en) * 2012-08-29 2018-03-15 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
US9790276B2 (en) 2012-12-18 2017-10-17 The Rockefeller University Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
EP2956480B1 (en) 2013-02-13 2019-09-04 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
KR102373930B1 (ko) 2013-09-13 2022-03-11 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
CN105899192B (zh) 2013-11-22 2019-08-13 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
CN107849087B (zh) * 2015-08-21 2022-09-06 豪夫迈·罗氏有限公司 在亲和层析中减少宿主细胞蛋白的方法
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
HUE057085T2 (hu) * 2015-10-16 2022-04-28 Hoffmann La Roche Egy rendszer mûködtetésére szolgáló eljárás és egy rendszer
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
US20190114464A1 (en) * 2016-03-10 2019-04-18 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN110691592A (zh) * 2017-05-30 2020-01-14 森永乳业株式会社 脑功能改善用组合物
EP3574020B1 (en) 2017-07-18 2024-05-15 The University of British Columbia Antibodies to amyloid beta
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
JP2023549809A (ja) 2020-11-16 2023-11-29 エフ． ホフマン－ラ ロシュ アーゲー Ｆａｂ高マンノースグリコフォーム
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
CN117783359A (zh) * 2023-12-28 2024-03-29 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) * 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
CN1191606A (zh) * 1995-06-06 1998-08-26 干细胞治疗公司 BL3造血干细胞上的糖蛋白gp105
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CN1279053C (zh) * 1999-03-04 2006-10-11 普雷西斯药品公司 含有D－氨基酸的β－淀粉样肽聚集的调节因子
CA2376693C (en) 1999-06-16 2013-09-10 Boston Biomedical Research Institute Immunological control of .beta.-amyloid levels in vivo
WO2001015655A2 (en) 1999-08-31 2001-03-08 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001039796A2 (en) 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
EP1257584B2 (en) 2000-02-24 2013-03-06 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
JP2005501220A (ja) 2000-12-19 2005-01-13 パラチン テクノロジーズ インク． ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別
ES2318006T3 (es) 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
EP1944040B1 (en) * 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20100748A1 (es) * 2005-12-12 2010-11-12 Hoffmann La Roche Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh
US20110070225A1 (en) * 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation

Also Published As

Publication number Publication date
KR101401159B1 (ko) 2014-05-29
UA99097C2 (ru) 2012-07-25
BRPI0619605B1 (pt) 2019-08-13
DOP2006000278A (es) 2007-07-15
JP2009520691A (ja) 2009-05-28
PT1960428E (pt) 2011-10-07
KR20080077132A (ko) 2008-08-21
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
AU2006326301A1 (en) 2007-06-21
CR10000A (es) 2008-07-29
NO346105B1 (no) 2022-02-21
IL191004A (en) 2013-08-29
WO2007068429A1 (en) 2007-06-21
US8906370B2 (en) 2014-12-09
US20090252724A1 (en) 2009-10-08
ECSP088524A (es) 2008-07-30
ZA200805038B (en) 2009-06-24
UY30003A1 (es) 2007-08-31
US20150165022A1 (en) 2015-06-18
SI1960428T1 (sl) 2011-10-28
PE20100684A1 (es) 2010-10-04
MA30038B1 (fr) 2008-12-01
DK1960428T3 (da) 2011-08-22
EP2377886A1 (en) 2011-10-19
CN101351476A (zh) 2009-01-21
RU2438706C2 (ru) 2012-01-10
AU2006326301B2 (en) 2011-04-21
NZ568241A (en) 2011-08-26
BRPI0619605A2 (pt) 2011-10-11
CN102659943A (zh) 2012-09-12
CY1114783T1 (el) 2016-12-14
PL1960428T3 (pl) 2012-02-29
PE20100748A1 (es) 2010-11-12
CA2632828C (en) 2012-07-10
CN101351476B (zh) 2013-04-03
HK1176075A1 (en) 2013-07-19
KR20120089483A (ko) 2012-08-10
EP1960428A1 (en) 2008-08-27
AR057233A1 (es) 2007-11-21
BRPI0619605B8 (pt) 2021-05-25
RU2008128138A (ru) 2010-01-20
ATE517923T1 (de) 2011-08-15
EP1960428B1 (en) 2011-07-27
ES2368591T3 (es) 2011-11-18
US9272031B2 (en) 2016-03-01
JO2824B1 (en) 2014-09-15
TWI382990B (zh) 2013-01-21
MY155286A (en) 2015-09-30
PE20071002A1 (es) 2007-11-19
CN102659943B (zh) 2015-07-01
HK1130066A1 (en) 2009-12-18
RS52004B (en) 2012-04-30
TW200736273A (en) 2007-10-01
JP5145241B2 (ja) 2013-02-13

Similar Documents

Publication Publication Date Title
NO20082874L (no) Antistoffer mot anyloid beta 4 med glykosylert i det variable omradet
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
MA28041A1 (fr) Molecules de liaison therapeutiques
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
Tischenko et al. Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G
BR0207151A (pt) Moléculas de aglutinação terapêuticas
BRPI0416211A (pt) il-23 e seu receptor; reagentes relacionados e métodos
BRPI0809042A8 (pt) Proteína de ligação a cd154 isolada, seu uso, e composição
CL2010000096A1 (es) Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06).
BRPI0712224B8 (pt) anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
NO20025354L (no) Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmåter
WO2005000246A3 (en) Methods and compositions for treating rheumatoid arthritis
DK0781845T3 (da) Anti-HMFG-antistoffer og fremgangsmåder til fremstilling heraf
ATE414718T1 (de) Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
Rispens et al. Hybrid IgG4/IgG4 Fc antibodies form upon ‘Fab-arm’exchange as demonstrated by SDS-PAGE or size-exclusion chromatography
PE20231080A1 (es) Anticuerpos que se unen a cd3 y cd19
DK1181366T3 (da) Mammale receptorproteiner, beslægtede reagenser og fremgangsmåder
KR940006602A (ko) 면역글로불린 이소타입에 대한 재조형 모노클로날 항체
BR112022004603A2 (pt) Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods